Tempus AI Awarded $9.5M Grant to Develop Autonomous Heart Failure Agent
On September 9, Tempus AI (NASDAQ:TEM) announced it was selected by the U.S. health research agency ARPA-H to develop an autonomous AI agent for treating heart failure patients without direct clinician involvement. The grant is worth up to $9.5 million and aims to address a critical shortage of cardiologists in many parts of the United States, where nearly half of counties lack one. Tempus plans to use its existing tools like Tempus Next—already analyzing over 2.7 million cardiology patients—and FDA-cleared ECG products as part of this initiative. The AI agent will monitor hospital records and home devices continuously, interact with patients about their care, and update medical records automatically. While the grant is relatively small compared to its $382.5 million quarterly revenue in Q2 2026, it signals a strategic expansion into cardiology. However, challenges remain: the AI agent has yet to be proven safe or effective through clinical trials, and Tempus reported widening operating losses despite strong cash reserves of $820.7 million. The company is also acquiring Personalis for approximately $1.5 billion in enterprise value, which could strain its financials if not offset by continued growth.
Tickers: $TEM
Topics: AI in Healthcare Funding and Grants Heart Failure Treatment Medical Technology